Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04057040 · ClinicalTrials.gov registry record · Phase 2
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
A Phase 2 study, sponsored by Protagonist Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT04057040 is a Phase 2 study that has completed, run by Protagonist Therapeutics. The registered enrollment target is 70 participants.
The verdict
NCT04057040, a Phase 2 study, has completed, sponsored by Protagonist Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is a Phase 2 study with an open-label dose escalation phase followed by a blinded withdrawal phase and an open label extension. The study is designed to monitor the PTG-300 safety profile and to obtain preliminary evidence of efficacy of PTG-300 for the treatment of phlebotomy-requiring polycythemia vera.
Interventions
- DRUG Placebo
- DRUG PTG-300
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2024-06-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04057040
The ClinicalTrials.gov registry entry for NCT04057040 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Protagonist Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04057040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04057040 about?
NCT04057040 is a clinical study titled "Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)". This is a Phase 2 study with an open-label dose escalation phase followed by a blinded withdrawal phase and an open label extension. The study is designed to monitor the PTG-300 safety profile and to obtain preliminary evidence of efficacy of PTG-300 for the treatment of phlebotomy-requiring polycyt...
What is the current status of trial NCT04057040?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2019-10-01. Estimated completion is 2024-06-17.
What interventions are being tested in trial NCT04057040?
The interventions under investigation include: Placebo (DRUG), PTG-300 (DRUG).
Who is sponsoring clinical trial NCT04057040?
This trial is sponsored by Protagonist Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.